Table 2:

Prevalence, crude incidence rates, and Cox proportional hazard models (univariate and multivariate) comparing risk of EHM conditions in DAA treated patients with and without SVR

	SVR			No SVR			Unadjusted		Minimally Adjusted*		Fully Adjusted**
Outcome	Prev/100	Events	IR/1000 PY	Prev/100	Events	IR/1000 PY	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Mixed cryoglobulinemia	1.09	20	0.22	1.1	7	0.9	0.24 (0.10-0.58)	0.0013	0.24 (0.10-0.56)	0.0011	0.23 (0.10-0.56)	0.0012
Glomerulonephritis	2.55	195	2.21	2.68	29	3.8	0.58 (0.39-0.85)	0.0055	0.57 (0.38-0.84)	0.0044	0.61 (0.41-0.90)	0.0126
Porphyria cutanea tarda	1.09	15	0.17	1.13	4	0.51	0.33 (0.11-0.99)	0.0482	0.33 (0.11-1.00)	0.0492	0.33 (0.11-1.03)	0.06
Lichen planus	1.43	141	1.58	1.52	26	3.37	0.47 (0.31-0.72)	0.0004	0.47 (0.31-0.72)	0.0004	0.46 (0.30-0.70)	0.0003
Non-Hodgkin lymphomas	1.35	168	1.88	1.55	18	2.33	0.86 (0.52-1.41)	0.54	0.85 (0.51-1.40)	0.52	0.86 (0.52-1.43)	0.57
Diabetes mellitus	31.47	1,290	21.04	35.78	116	23.11	0.94 (0.78-1.14)	0.53	0.93 (0.77-1.13)	0.49	0.98 (0.81-1.19)	0.86

Abbreviations: IR, incidence rate; PY, person-years; CI, confidence intervals

^*Adjusted for age, sex, race/ethnicity

^**Adjusted for above plus pre-existing alcohol abuse, drug abuse, HIV, hypertension, cirrhosis, cirrhosis complications, HBV, pre- and post-utilization, treatment experienced, and HCV genotype